Last updated: April 25, 2026
Astellas Pharma Inc. v. Lupin Ltd. | 1:16-cv-00908: Litigation Summary and Patent/Claim Analysis
What is the case and what did Astellas assert?
Astellas Pharma Inc. (“Astellas”) brought a patent infringement action against Lupin Ltd. (“Lupin”) under 35 U.S.C. § 271 in the U.S. District Court for the District of Delaware (case no. 1:16-cv-00908). The litigation is part of a U.S. Hatch-Waxman patent dispute framework tied to Lupin’s ANDA pathway and Astellas’s Orange Book-listed patents for an Astellas branded drug product.
The case record in public sources identifies:
- Court: U.S. District Court for the District of Delaware
- Case number: 1:16-cv-00908
- Parties: Astellas Pharma Inc. (plaintiff) vs Lupin Ltd. (defendant)
- Core posture: patent infringement claims tied to Lupin’s generic marketing efforts under the ANDA framework.
When did the litigation occur procedurally?
From the case metadata and docket-linked reporting available in public legal databases:
- Filed: 2016 (case number indicates the 2016 filing year)
- Public record linkage: the case appears as a completed federal matter in 2016-era ANDA litigation sets associated with the District of Delaware Hatch-Waxman docket.
(The public index sources available here identify the docket presence and case identity, but do not supply the full claim chart content, claim-by-claim rulings, or final judgment text in the excerpts accessible.)
What patents and claims were at issue?
Publicly surfaced case-identifying records confirm the litigation exists and identify the parties and docket number, but do not provide the specific asserted patent list, the asserted claims, claim constructions, or the court’s claim-by-claim infringement and invalidity holdings within the accessible excerpted sources.
As a result, this analysis focuses on the structure of the dispute and the decision workflow that typically governs these cases in the District of Delaware, while staying within what the available record can support.
How did the dispute typically proceed in this Hatch-Waxman posture?
For ANDA patent litigation under Hatch-Waxman in the District of Delaware, the procedural sequence usually drives the practical outcome:
- ANDA listing and patent assertion triggers
- Astellas relies on Orange Book patents listed for the branded product.
- Lupin’s ANDA filing produces statutory notice events (often the predicate for suit).
- Pleading stage
- Astellas asserts infringement of specified patents and claims.
- Lupin contests infringement and asserts invalidity and/or non-infringement defenses.
- Markman phase
- Claim construction occurs and becomes central to the infringement/invalidity path.
- Infringement and invalidity
- The court resolves infringement based on the constructed claim scope and the ANDA product disclosures.
- Invalidity follows the statutory grounds pleaded (commonly § 102/§ 103 and sometimes § 112).
- Potential outcomes
- Dismissal, stipulation, settlement, or merits judgment.
- Any merits decision typically results in an injunction framework tied to 35 U.S.C. § 271(e)(2) and the 30-month stay mechanics.
What is the likely commercial impact for Astellas and Lupin?
In this dispute category, the commercial impact flows from whether the asserted patents are held to be infringed and not invalid, or whether the litigation resolves through settlement.
Even without the excerpted final rulings here, the business levers are consistent:
- If infringement and validity survive: Lupin’s launch timing stays blocked by the statutory framework (and any injunction outcome).
- If invalidity or non-infringement prevails: Lupin can proceed with launch at risk or after judgment, depending on the procedural posture.
- If settlement occurs: the economics shift to the settlement terms, often including agreed launch dates and/or non-marketing commitments.
Litigation status and outcome
The accessible public references confirm the case identity and existence in the District of Delaware ANDA litigation docket. They do not provide the final judgment text, dispositive motions outcomes, or settlement/injunction terms within the accessible excerpted material.
Accordingly, the only defensible statement is that this litigation proceeded as a federal Hatch-Waxman patent infringement action on the specified docket, with no court-held merits findings or final damages/injunction terms supplied in the accessible sources.
Actionable analysis for R&D and investment: what to extract from this docket
Even where the full merits record is not visible in the supplied excerpts, the docket can still be translated into actionable diligence steps for an investor or IP due diligence team:
1) Identify the asserted Orange Book patents and claim set
For downstream scoring of patent strength and regulatory risk, the primary data object is:
- Asserted patents: publication numbers and expiration dates
- Asserted claims: claim numbers and independent claim anchors
- Claim construction positions: key terms disputed at Markman
Without those elements, it is not possible to calculate a litigation-strength score. This response therefore does not produce a strength ranking.
2) Confirm whether the outcome was merits, dismissal, or settlement
A settlement or stipulation changes the risk model:
- Settlement: launch timing and scope become key; patent strength becomes second-order
- Merits decision: claim interpretation and validity holdings drive long-term risk
This docket’s public excerpts do not provide the outcome classification.
3) Map the infringement theory to ANDA product disclosures
For generic challengers, the most predictive technical diligence includes:
- Core formulation elements and dosing form
- Bioequivalence design and any relevant pharmacokinetic constraints
- Any structural/formulation claims that map to ingredient lists or manufacturing process disclosures
This requires the asserted claim set and product-specific record, which the accessible excerpts do not include.
4) Track the next filings
In this case type, follow-on events often determine the practical value of any patents:
- Continuations or related family members
- Appellate history (if any)
- Later reexamination or post-grant proceedings (if initiated)
No such event details are in the accessible excerpt.
Case fact sheet (from available docket identifiers)
| Item |
Value |
| Plaintiff |
Astellas Pharma Inc. |
| Defendant |
Lupin Ltd. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:16-cv-00908 |
| Year of filing |
2016 |
| Claim type (category) |
Hatch-Waxman ANDA patent infringement (35 U.S.C. § 271(e)(2)) |
| Accessible outcome detail in provided sources |
Not provided in excerpted material |
Key Takeaways
- Astellas v. Lupin (1:16-cv-00908) is a District of Delaware Hatch-Waxman patent infringement case filed in 2016, with Astellas as plaintiff and Lupin as defendant.
- The accessible public excerpts used here confirm case identity and posture, but do not provide the asserted patent list, asserted claims, claim construction, or final disposition in a way that supports a claim-level infringement/validity analysis.
- For business decisions, the dossier should be built around: asserted Orange Book patents, independent claims, Markman constructions, and the disposition type (merits vs dismissal vs settlement). Those elements determine launch and long-term IP risk.
FAQs
-
What court heard Astellas Pharma Inc. v. Lupin Ltd.?
The case is in the U.S. District Court for the District of Delaware.
-
What is the docket number?
1:16-cv-00908.
-
What type of case is it?
A Hatch-Waxman ANDA patent infringement action in federal court involving Orange Book-listed patents.
-
Which specific patents were asserted in this case?
The asserted patent list is not provided in the accessible excerpted sources used here.
-
What was the litigation outcome?
The disposition details (final ruling or settlement terms) are not provided in the accessible excerpted sources used here.
References
- Bloomberg Law. Astellas Pharma Inc. v. Lupin Ltd., No. 1:16-cv-00908 (D. Del.).
- Justia Dockets. Astellas Pharma Inc. v. Lupin Ltd., No. 1:16-cv-00908 (D. Del.).
- UniCourt. Astellas Pharma Inc. v. Lupin Ltd., No. 1:16-cv-00908 (D. Del.).
